![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 42, 29838-29842, October 15, 1999
§,
From the
Division of Basic Sciences and Molecular and
Cellular Biology Program, Fred Hutchinson Cancer Research Center,
Seattle, Washington 98104 and the ¶ Departments of Pathology and
Cell Biology, Baylor College of Medicine, Houston, Texas 77030
| |
ABSTRACT |
|---|
|
|
|---|
We have characterized the functional role of SR
protein-mediated exon/exon associations in the alternative splicing of
exon 5 of chicken cardiac troponin T (cTnT). We have previously shown that SR proteins can promote the association of the alternative exon 5 with the flanking constitutive exon 6 of this pre-mRNA. In this
study, we have shown that when exons 2, 3, and 4 of the cTnT
pre-mRNA are spliced together, the composite exon 2/3/4 contains an
additional SR protein binding site. Furthermore, we have found that SR
proteins can also promote interactions between the pairs of exons
2/3/4-5 and 2/3/4-6. We then asked whether the SR protein binding sites
in these exons play a role in cTnT alternative splicing in
vivo. We found that the SR protein binding sites in exons 2/3/4 and 6 promote exon 5 skipping, and it has previously been shown that
the SR protein binding site in exon 5 promotes exon 5 inclusion. Consistent with these results, we find that the SR protein-mediated association of exon 2/3/4 with 6 is preferred over associations involving exon 5, in that exons 2/3/4 and 6 are more efficient than
exon 5 in competing an SR protein-mediated exon/exon association. We
suggest that the relative strengths of SR protein-mediated associations
of alternative and constitutive exons play a role in determining
alternative splicing patterns.
During splicing of some precursor messenger RNA (pre-mRNA),
splice sites that are short and poorly conserved must be properly chosen and brought together across introns, some as large as 100 kilobases (1). The selection of any pair of splice sites is the result
of interactions of each individual splice site with the splicing
machinery combined with the pairing of the selected splice sites with
one another across introns. The relative strength of these interactions
appears to vary greatly between splice site pairs during alternative
splicing, in which as many as hundreds of different mRNAs are
formed from single genes (2, 3). To understand how splice site pairs
are chosen, research has focused on identifying the factors that are
responsible for this variation during alternative splicing.
SR1 proteins are a family of
splicing factors that appear to play an important role in alternative
splicing in that individual SR proteins can influence the selection of
distinct alternative splice sites (4-6). Insight into the mechanism of
SR protein function has come through the identification of RNA
sequences to which they bind and appear to influence splicing. These
sequences are characteristically composed of purine-rich sequences that reside within an alternatively spliced exon, and when these sequences are found to be important for the selection of the alternative exon
where they reside, they are termed exonic splicing enhancers (1, 5). SR
proteins appear to function at exonic splicing enhancers by promoting a
variety of interactions that result in the interaction of exons across
introns. SR proteins, bound to exonic enhancers, appear to promote
interactions of both the U1 and U2 snRNPs1 with adjacent
splice sites (7-10). These splicing snRNPs may interact with those
bound to a flanking exon and in this way promote interactions of exons
across introns (11). As well, SR proteins, independent of other
factors, can promote a specific association between an exonic
enhancer-containing alternative exon and a flanking, constitutive exon,
which also has an SR protein binding site (8). SR proteins may perform
this function on a number of pre-mRNAs, because sequence analysis
reveals that when purine-rich SR protein binding sites are found in
alternative exons, they tend to also be found in one or more of the
constitutive exons that flank the alternative exon, based on sequence
comparisons (8).
The finding that SR proteins can promote exon/exon associations between
alternative and constitutive exons suggests that SR protein-mediated
exon/exon associations could be important for the selection of exon
pairs during alternative splicing. To address this hypothesis, we have
analyzed a splicing event that involves SR protein binding sites in
contiguous exons: the alternative inclusion of exon 5 into the chicken
cardiac troponin T (cTnT) mRNA. Exon 5 is included in mRNAs in
embryonic skeletal and cardiac muscle and is excluded from mRNAs in
the adult (12). It has previously been shown that exon 5 contains an SR
protein binding site that is essential for exon 5 inclusion (13) and
that SR proteins can promote the association of the alternative exon 5 with the flanking constitutive exon 6 of this pre-mRNA (8). In this
study, we show that SR proteins can also promote interactions between
the pairs of exons 2/3/4-5 and 2/3/4-6, where exon 2/3/4 is the
composite of exons 2, 3, and 4 spliced together. We also show that SR
protein binding sites in the flanking constitutive exons, exons 2/3/4
and 6, appear to promote exon 5 skipping in vivo. Consistent
with these results, we find that the SR protein-mediated association of
exon 2/3/4 with 6 is preferred over associations involving exon 5, in
that exons 2/3/4 and 6 are more efficient than exon 5 in competing an
SR protein-mediated exon/exon association. We suggest that the relative
strengths of SR protein-mediated associations of alternative and
constitutive exons play a role in determining alternative splicing patterns.
UV Cross-linking--
UV cross-linking of RNA to purified SR
proteins was performed similar to that previously described (13). Exon
2/3/4 RNA was transcribed from a synthetic oligonucleotide template
with T7 polymerase and labeled using [
The samples were placed on ice and UV irradiated at 120,000 µJ for 7 min at 254 nm (Stratalinker 1800, Stratagene, La Jolla, CA). Following
UV irradiation, each sample was incubated with 1 µl of RNase A and T1
(Ambion) at 37° for 30 min, mixed with an equal volume of protein
sample buffer, incubated at 90° for 3 min, and resolved by 10%
SDS-PAGE. The gels were exposed to a PhosphorImager, and the relative
signals were quantified with Image/Quant (Molecular Dynamics, Sunnyvale CA).
RNA Affinity Chromatography--
RNA affinity chromatography
assays for SR protein-mediated exon/exon associations were performed as
described previously (8). RNA affinity columns containing exon 5/UP or
exon 6 were assembled using R17-exon fusion RNAs. For each column, 8 µg of R17-exon RNA was bound to 10 µg of R17-glutathione
S-transferase protein affixed to 70 µl of
glutathione-agarose. The RNA affinity columns were incubated for 1 h at 30 °C in a volume of 220 µl in 20 mM Hepes, pH
7.6, 220 mM KCl, 3.6 mM MgCl2, 3.6 mM ATP, and 4.5 mM creatine phosphate with 100 µl of a solution of 20 µg/ml bovine serum albumin, 10 µg/ml
Escherichia coli tRNA, with or without 2.6 µg
of calf thymus or HeLa SR proteins. The final concentration of SR
proteins in the defined system was 12 µg/ml, whereas the SR protein
concentration in standard splicing reactions with HeLa nuclear extract
is approximately 30 µg/ml (15).
Radiolabeled RNAs were added to the columns at the same time that SR
proteins were added. Control RNA was transcribed from Bluescript KS+
linearized with XbaI (small) or XhoI (large). The exon 4, exon 2/3/4, and exon 2 m/3 m/4 RNAs (sequence shown in Fig.
1A) were transcribed from synthetic oligonucleotide
templates. All of these RNAs were transcribed with T7 polymerase and
labeled using [
Equal amounts of the exon/intron RNAs were mixed with a set amount of
control RNA to make normalized RNA samples. A part of these samples was
saved as preload, and the rest was added in equal amounts to RNA
affinity columns. To some columns competitor RNAs were added (exon
5/WT, exon 2/3/4, or exon 6), which were synthesized with T7 polymerase
and were not radiolabeled (14). In these experiments where competitors
were added (Fig. 4), the radiolabeled 2/3/4 RNA concentration was 10 pmol/reaction, and the tRNA concentration was 20 µg/ml. Following
incubation, columns were washed four times at 4 °C in Buffer S (8).
One-third of each sample was loaded onto a 6 M urea, 5%
acrylamide gel. The gels were exposed to a PhosphorImager, and the
relative signals were quantified with Image/Quant (Molecular Dynamics).
The column affinity of an exon was computed by dividing the signal from
the exon RNA by the signal from the control RNA. The change in column affinity of an exon because of SR proteins was computed by dividing the
column affinity with SR proteins by the column affinity without SR proteins.
DNA Construction, Transient Transfection, and RNA
Analysis--
The WT minigene construct is a derivative of
Transient transfection of QT35 and primary chicken breast muscle
cultures, RNA isolation from transfected cells, and reverse transcription of RNA samples was performed as described previously (17). PCR amplification of reverse transcription reactions was performed under standard conditions with the following two
oligonucleotides: TNTE1, 5'-CATTCACCACATTGGTGTGC; and PBSA,
3'-CCTACAAGATTGTCATC.
A fraction of the PBSA 3' oligonucleotide in the PCR reaction was
end-labeled using [ Exon 2/3/4, the Composite of Exons 2, 3, and 4 Spliced Together,
Can Bind to SR Proteins--
To analyze SR protein associations with
the cTnT pre-mRNA, we asked whether SR proteins could interact with
exons that are upstream of exon 5. In addition to studying the
biochemical properties of exon 4 alone, we considered that exon 4 may
be part of a larger exon, of exons 1, 2, 3, and 4 spliced together,
when it is spliced to exon 5. Exons 2 and 3 are moderately purine-rich
and, when spliced to exon 4, could generate an SR protein binding site
and thereby influence the splicing pattern of exon 4. Thus, we have analyzed the SR protein binding characteristics of the composite of
exons 2, 3, and 4 spliced together, which we refer to as exon 2/3/4
(Fig. 1A).
To test whether exon 2/3/4 can bind SR proteins, we asked whether exon
2/3/4 could form a UV cross-linked species with SR proteins.
Radiolabeled exon 2/3/4 (3 pmol) was incubated with purified SR
proteins and nonspecific competitor RNA (50 pmol) under splicing
conditions and subsequently exposed to UV irradiation at 254 nm, which
can create covalent bonds between protein and RNA (13). The reactions
were then treated with RNase A and T1 to displace uncross-linked RNA,
and the radiolabeled proteins were resolved by 10% SDS-PAGE. In these
experiments, exon 2/3/4 formed cross-linked species with several SR
proteins (Fig. 1B, lane 1). To determine the
specificity of the cross-link, identical reactions were performed in
the presence of five different competitor RNAs: exon 2/3/4; exon 2 m/3
m/4, which is similar to exon 2/3/4 except it has 13 purine to
pyrimidine mutations in the exon 2 and 3 region (Fig. 1A);
full-length exon 2; exon 3; and exon 4. Each competitor was tested at
two concentrations: 10 and 30 pmol/reaction. Addition of the exon 2/3/4
competitor RNA led to a decrease in the cross-linking efficiency of
radiolabeled exon 2/3/4 to all the SR proteins (lanes 2 and
3). The exon 2 m/3 m/4, full-length exon 2, exon 3, and exon
4 competitor RNAs, in contrast, were significantly less efficient at
inhibiting the cross-linking efficiency (lanes 4-11). For
example, the cross-link to SRp55 was inhibited 4- and 12-fold by 10 and
30 pmol of exon 2/3/4 competitor, respectively, 1.3- and 1.6-fold for
the same amounts of exon 2 m3m4, 1.6- and 1.8-fold for exon 2, 1- and
2-fold for exon 3, and 1.5- and 3-fold for exon 4. These results
suggest that an efficient SR protein binding site is created by the
splicing together of exons 2, 3, and 4.
SR Proteins Are Sufficient to Promote the Associations of Exon
2/3/4 with Exon 6 and Exon 2/3/4 with Exon 5/UP--
In a previous
study, we found that SR proteins are sufficient to promote a specific
association of exon 6 with exon 5/UP, an exon 5 mutant that has an
enhanced SR protein binding site (18). Thus, we wondered whether SR
proteins could also promote associations of exon 2/3/4 with exons 5 and/or 6. To test this prediction, we assayed the affinities of 1)
radiolabeled exon 2/3/4 and exon 4 RNAs for exon 5/UP affinity columns
and 2) radiolabeled exon 2/3/4 and exon 2 m/3 m/4 for exon 6 affinity
columns. In these experiments, the radiolabeled RNAs were incubated
with the affinity columns along with fixed amounts of radiolabeled
control RNAs both in the presence or absence of SR proteins. To assay for relevant interactions, the concentration of SR proteins in these
experiments is 12 µg/ml, which is on the same order as that present
in standard splicing reactions with HeLa nuclear extract (15).
Following several washes, RNA was extracted from the columns and
resolved on a 5% urea-PAGE gel. Note that in Fig. 2 the long exon
2/3/4 and 2 m/3 m/4 RNAs (labeled E) are incubated with a short control
RNA (labeled C), and the short exon 4 RNA (labeled E) is incubated with
a long control RNA (labeled C).
In these experiments (Fig. 2), SR
proteins reproducibly resulted in a >5-fold increase in the amount of
exon 2/3/4, which bound to both exon 5/UP columns (lanes 2 and 3) and exon 6 columns (lanes 10 and
11). In contrast, the addition of SR proteins did not result
in an increase in the amount of exon 4, which bound to exon 5/UP
columns (lanes 7 and 8), or in the amount of exon 2 m/3 m/4, which bound to exon 6 columns (lanes 13 and
14). Analysis of supernatant fractions from these incubation
reactions shows that the amounts of RNAs present at the end of the
incubations were the same with or without SR proteins (lanes
4 and 5, and data not shown). This result indicates
that SR proteins do not influence the stability of the these RNAs in
the binding reaction. The supernatant signal does not diminish with SR
proteins because radiolabeled exon RNAs are in molar excess of column
exon RNA. These results suggest that SR proteins are sufficient to
promote the associations of exon 2/3/4 with exon 5/UP and exon 2/3/4
with exon 6.
SR Protein Binding Sites in Exons 2/3/4 and 6 Promote Exon 5 Skipping--
The findings that SR proteins can promote exon/exon
associations between the pairs of exons 5/UP-6 (8), 2/3/4-5/UP, and 2/3/4-6 suggested that the SR protein binding sites in each of these
exons may play a role in cTnT splicing. The SR protein binding sites in
alternatively included exons, such as exon 5, are generally found to be
essential for inclusion of the alternative exon (1, 13). However, the
functional role of the SR protein binding sites in constitutive exons,
such as exons 2/3/4 and 6, remained unexplored.
To characterize the role of purine-rich SR protein binding sites in
exon 2/3/4 and exon 6 in the splicing of cTnT, we have mutated these
sites and assayed their effects on cTnT splicing in vivo.
Four minigenes were constructed (Fig.
3A): WT, which contains
wild-type cTnT genomic sequence; 2 m3m, which has the mutations of
purine residues in exons 2 and 3 described above (see Fig.
1A); 6 m, which has mutations of purine residues in exon 6 (8); and 2 m3m6 m, which has a combination of the mutations made
in exons 2, 3, and 6. The 2 m3m and 6 m mutations can be expected
to affect the SR protein binding capacity of exons 2/3/4 and 6 in
vivo (Refs. 8 and 13, Figs. 1 and 2), although it is formally
possible that these mutations could also affect the associations of
additional factors. These minigenes were transfected into QT35
fibroblasts and primary chicken embryo skeletal muscle cultures. RNA
was subsequently isolated from the transfected cells, and the splicing
patterns of each minigene were assayed by reverse transcriptase-PCR. In
these experiments, the mutations affected the relative ratio of
mRNAs including and excluding exon 5. In QT35 cells, where the
wild-type cTnT minigene exhibits exon 5 inclusion levels of 42%, both
the 2 m3m and 6 m mutant minigenes exhibit increased exon 5 inclusion levels in these cells to 59 and 61%, respectively (Fig.
3A). The combination mutant 2 m3m6 m exhibited an exon 5 inclusion level of 73% in QT35 cells, which is higher than either of
the individual mutants. Single mutations in exon 2 and exon 3 each show
a partial increase of exon 5 inclusion at 47 ± 4% and 47 ± 3%, respectively, although it is not clear whether these increases are
significant. This result indicates that at least two purine-rich
regions in exon 2/3/4 need to be mutated to significantly affect its
splicing. In muscle cells, the mutant minigenes 2 m3m, 6 m, and 2 m3m6 m showed slight increases in exon 5 inclusion at 94, 98, and 95%,
respectively, where the WT exon 5 inclusion is already high at 89%.
These results indicate that the purine-rich sites in exons 2, 3, and 6 promote exon 5 skipping. Alternatively, the mutated forms of exons 2, 3, or 6 could possibly be acting as inhibitors of exon 5 inclusion. The simplest interpretation of all of these results is that SR proteins bound to exons 2/3/4 and 6 promote exon 5 skipping.
The SR Protein-mediated Association of Exon 2/3/4 with Exon 6 Is
Preferred over Associations Involving Exon 5--
The finding that the
SR protein binding sites in exons 2/3/4 and 6 promote exon 5 skipping
suggests that SR proteins may prefer to promote the association of exon
2/3/4 with exon 6 instead of associations of exons 2/3/4 or 6 with exon
5. To test this hypothesis, we performed an in vitro
competition assay for exon/exon associations where we assayed the
relative ability of exons 2/3/4, 5, and 6 to disrupt the SR
protein-mediated association of exon 2/3/4 with exon 6. In these
experiments, radiolabeled exon 2/3/4 was incubated with exon 6 columns
and SR proteins in the presence of exon 5/WT, exon 2/3/4, or exon 6 as
competitor RNAs. Following several washes, RNA was extracted from the
columns and resolved on a 5% urea-PAGE gel.
In the first experiment (Fig.
4A), we compared inhibition
capacity of exon 5/WT with that of exon 2/3/4. In this experiment, exon
5/WT inhibited the 2/3/4-6 interaction 3- and 7-fold with a 30 and 300 pmol/reaction, respectively (lanes 4 and 5),
whereas exon 2/3/4 inhibited the 2/3/4-6 interaction 6- and 13-fold
with a 30 and 300 pmol/reaction, respectively (lanes 6 and
7). In the second experiment (Fig. 4B), we
compared the inhibition capacity of exon 5/WT with that of exon 6. In
this experiment, exon 5/WT inhibited the 2/3/4-6 interaction 1.3- and
3-fold with a 15 and 150 pmol/reaction, respectively (lanes
4 and 5), whereas exon 6 inhibited the 2/3/4-6
interaction 2.3- and 5.5-fold with a 15 and 150 pmol/reaction,
respectively (lanes 6 and 7). Thus, both exon
2/3/4 and exon 6 were each consistently 1.8-fold more efficient than
exon 5/WT at disrupting the SR protein-mediated association of the
radiolabeled exon 2/3/4 for the exon 6 column. We performed these
experiments six times; 1.8-fold effects were observed each time we
performed these experiments. These results suggest the SR
protein-mediated in vitro association of exon 2/3/4 with 6 is preferred over associations involving exon 5, which is consistent with the observation that the SR protein binding sites in exon 2/3/4
and 6 promote alternative exon 5 skipping in vivo. We
suggest that the relative strengths of SR protein-mediated associations between exons 2/3/4, 5, and 6 play a role in cTnT alternative splicing
(Fig. 4C).
The relative strengths of exon/exon associations appear to vary
between distinct exon pairs during alternative splicing (2, 3). To
understand how alternative splicing patterns are established, it will
be critical to identify the molecular mechanisms that give rise to this
variation. In this study, we have characterized the role of SR
protein-mediated exon/exon associations in this process. Previous
results have shown that SR proteins, bound to exons, may function to
promote the interactions of exons across introns, both by promoting
exon/exon associations directly and as well by promoting snRNP
associations with splice sites (7-10). In this study, we have analyzed
the chicken cardiac troponin T pre-mRNA, which has SR protein
binding sites in multiple contiguous exons: the constitutive exons
2/3/4 and 6 and the alternative exon 5. With this pre-mRNA, we show
that the SR protein binding sites in the constitutive exons appear to
promote alternative exon skipping in vivo. These results are
consistent with our additional findings that the SR protein-mediated
in vitro association of the two constitutive exons (exon
2/3/4 with exon 6) is preferred over SR protein-mediated associations
involving the intervening alternative exon (exon 5). We suggest that
the relative strengths of SR protein-mediated associations of
alternative and constitutive exons play a role in determining
alternative splicing patterns.
SR protein binding sites are not likely to be the only elements that
influence the relative strengths of exon/exon associations during cTnT
alternative splicing, as is suggested by the finding that the SR
protein binding sites in exons 2/3/4 and 6 are not absolutely essential
for exon 5 skipping. For example, the efficiency of association of
splicing snRNPs with a particular exon, which can interact with snRNPs
bound to another exon, is also likely to influence the efficiency of
particular exon/exon associations (1, 11, 19). These mechanisms play a
role in cTnT splicing, because exon 5 inclusion can be enhanced by
improving the base complimentarity of its 5'-splice site for the U1
snRNA (16, 20). Another element that likely influences exon/exon
associations is the constitutive preference for splicing proximal
exons. This appears to be a common feature of RNA splicing, because, in
general, the most abundant mature mRNAs contain exons spliced in
order (2). The mechanisms that underlie this preference are unknown, although the co-transcriptional nature of splicing suggests that the
pairing of two proximal exons could be finished before the synthesis of
another distal exon (21, 22). The finding that exon 5 skipping in cTnT
is not simply a default splicing pathway indicates that these
mechanisms are at work even in cases of the splicing of weak,
alternative exons. Thus, the order that the exons are organized in the
pre-mRNA, the relative strengths of the splice sites of each exon,
and the relative strengths of SR protein-mediated exon/exon
associations likely act in combination to affect the relative
efficiencies of particular exon/exon associations during
alternative splicing.
We have also found that the assembly of SR protein binding sites can
depend upon previous splicing events; exon 4 appears to bind
efficiently to SR proteins only when it is spliced to exons 2 and 3 in
the composite exon 2/3/4. The apparent involvement of at least two
purine-rich regions in the splicing of exon 2/3/4 suggests that the
long purine-rich sequence in exon 2/3/4 may bind a complex of multiple
SR proteins. Plus, the finding that this SR protein binding site
influences exon 5 inclusion indicates that the alternative splicing of
exon 5 is linked to other splicing events that are distant on the
pre-mRNA from the alternative splicing event. It follows that part
of the regulation of exon 5 inclusion could occur through controlling
the relative timing of these distant splicing events. For example,
delayed splicing of exons 2, 3, and 4, which synthesizes the SR protein
binding site in exon 2/3/4, could increase the chance that exon 5 could
compete with exon 4 for splicing to exon 6. Thus, it appears that
regulation of exon 5 inclusion is not limited to intronic elements
previously shown to promote muscle-specific exon inclusion (17, 23). Clearly, an assumption in this model is that exons 2, 3, and 4 are
spliced together when the purine residues in exons 2 and 3 affect exon
5 inclusion, which remains to be determined. There are other examples
where the synthesis of a splicing element is dependent upon a previous
splicing event. In the pre-protachykinin pre-mRNA, the splicing of
exons 4 and 5 places the strong 5'-splice site proximal to exon 4, which promotes the splicing of exon 4 to exon 3 (19). In addition, the
splicing of exons 6 and 8 of the
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]GTP. 3 pmol
of radiolabeled exon 2/3/4 RNA was incubated with 500 ng of total calf
thymus SR proteins and 50 pmol of nonspecific competitor RNA (13) under
splicing conditions for 10 min at 30°. To some samples other
nonradiolabeled RNAs were added as competitors at two concentrations
each (10 and 30 pmol/reaction). These exon RNAs (2/3/4, 2 m/3 m/4, 2, 3, and 4) were transcribed from a synthetic oligonucleotide template
with T7 polymerase (14). RNAs were purified from 5% urea-PAGE gels and
quantified using a spectrophotometer. Their sequences are shown in Fig.
1A except for the complete sequence of exon 2, which
is UAUGCCUUGCAUGUCGGACUCUGAAGAGGUCGUUGAAGGAUACGACGA.
-32P]GTP (14). The RNAs for a given
experiment were transcribed in parallel with the ratios of labeled
GTP/cold GTP set such that all the RNAs would have the same
molar-specific activity. RNAs were purified from 5% urea-PAGE gels and
quantified using a scintillation counter.
PB.SA
(16); where
PB.SA has a short mutation in exon 4 that creates a
BamHI site, the WT minigene in this manuscript has wild-type
exon 4. The nucleotide sequence changes made in the mutant minigenes
are described in detail in Figs. 1A and 3. All mutations
were created using site-directed mutagenesis and were confirmed by sequencing.
-32P]ATP and T4 kinase. PCR
products were resolved by 6% urea-PAGE. The gels were exposed both to
film and to a PhosphorImager, and the relative signals were quantified
with Image/Quant (Molecular Dynamics). The percent of exon 5 inclusion
from a given PCR reaction was computed by dividing the signal from the
exon 5 inclusion product by the sum of the signals of exon 5 included
and exon skipped product (multiplied by 100). The percent exon 5 inclusion for a given minigene is the mean of the percent exon 5 inclusion from at least three independent transfections.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (41K):
[in a new window]
Fig. 1.
SR proteins interact with the composite exon
of 2, 3, and 4 spliced together (exon 2/3/4). A, the
nucleotide sequence of the exon 2/3/4 RNA, which begins at nucleotide
23 of exon 2 and extends through exons 3 and exon 4 of cTnT (12). The
exon boundaries are indicated by vertical lines. Also shown
is the nucleotide sequence of the exon 2 m3m4 RNA, which is similar to
the exon 2/3/4 RNA except that 13 purine residues are changed to
pyrimidines in exons 2 and 3. B, the UV cross-link of exon
2/3/4 to SR proteins. Shown are the UV cross-linked species from a
reaction containing radiolabeled exon 2/3/4 RNA and purified SR
proteins (lane 1). Shown are the UV cross-linked species
from similar reactions, which also contain various competitor RNAs at
two concentrations (10 pmol/reaction and 30 pmol/reaction): exon 2/3/4
(lanes 2 and 3), exon 2 m3m4 (lanes 4 and 5), exon 2 (lanes 6 and 7), exon 3 (lanes 8 and 9), or exon 4 RNA (lanes
10 and 11). The identity of the radiolabeled SR
proteins is depicted on the left and is based upon their
mobility relative to molecular weight standards.

View larger version (50K):
[in a new window]
Fig. 2.
SR proteins can promote associations both of
exon 2/3/4 with exon 5 and also of exon 2/3/4 with exon 6. The two
panels on the left (lanes 1-8) show the
associations of exon 2/3/4 and exon 4 with the exon 5/UP column in the
presence and absence of SR proteins. The relative amount of exon and
control RNAs added to R17-exon 5/UP affinity columns is shown for exon
2/3/4 (lane 1) and exon 4 (lane 6). The signals
from the exon 2/3/4 and exon 4 RNAs are shown from complexes assembled
in either the absence (lanes 2 and 7,
respectively) or presence (lanes 3 and 8,
respectively) of SR proteins at a concentration similar to that in
standard in vitro splicing reactions. Also shown are the
signals for supernatant fractions from the complexes shown in
lanes 2 and 3 (lanes 4 and
5, respectively). The two panels on the right
(lanes 9-14) show the association of exon 2/3/4 and exon 2 m/3 m/4 with exon 6 columns in the presence and absence of SR proteins.
The relative amount of exon and control RNAs added to exon 6 affinity
columns is shown for exon 2/3/4 (lane 9) and exon 2 m/3 m/4
(lane 12). The signals from exons 2/3/4 and 2 m/3 m/4 are
shown from complexes assembled in either the absence (lanes
10 and 13, respectively) or presence (lanes
11 and 14, respectively) of SR proteins. The relative
migration of the exon RNA and the control RNA is indicated to the
right of each panel by an E and a C,
respectively.

View larger version (24K):
[in a new window]
Fig. 3.
The purine residues in exons 2, 3, and 6 promote efficient skipping of exon 5. Illustrated are minigenes
that express a genomic fragment of chicken cTnT from exon 1 to exon 6 with exon 6 fused to a genomic fragment of skeletal
-actin. The
shaded boxes indicate mutation of purine residues
within that exon. The mutations in exons 2 and 3 are identical to those
shown in Fig. 1A. The mutation in exon 6 replaces a
58-nucleotide purine stretch with exon 2 of skeletal troponin I (13).
The minigenes were transfected into QT35 fibroblasts and primary
chicken embryo skeletal muscle cultures. Subsequently, splicing was
assayed by reverse transcriptase-PCR with the oligonucleotides. For
each minigene, the percentage of spliced mRNA that includes exon 5 is shown. Each percentage was averaged from at least three independent
transfections. The standard deviations from the mean are indicated to
the right of each percentage. Also shown are previous
results for two exon 5 mutants placed here for comparison (13). Also
shown are reverse transcriptase-PCR products from one transfection for
the WT, 2 m3m, 6 m, and 2 m3m6 m minigenes. The film exposures
were chosen such that the lanes would exhibit similar overall
intensities to allow easy comparison. Although these calculations are
unaffected by exposure times to the PhosphorImager, the percentages
were calculated from approximately the same exposure times for each
transfection. The standard deviations are less than 5%, because the
relative ratio between exon 5 included RNA, and exon 5 skipped RNA,
which is internal to each sample, is isolated from pipetting errors.
These ratios also have been found to be unaltered by changes of the
number of cycles of the PCR reaction and are the same as that observed
by primer extension (data not shown). The reverse transcriptase-PCR
products, which include exon 5 and skip exon 5, are indicated to the
left by inc and skp,
respectively.

View larger version (31K):
[in a new window]
Fig. 4.
The SR protein-mediated interaction of exon
2/3/4 with 6 in vitro is preferred over interactions
involving exon 5. A and B, the competition
of the SR protein-mediated association of exon 2/3/4 with exon 6. The
relative amount of exon 2/3/4 and control RNA added to exon 6 affinity
columns is shown (A and B, lane 1).
The signals from exons 2/3/4 are shown from complexes assembled in
either the absence (A and B, lane 2)
or presence (A and B, lane 3) of SR
proteins. The signals from complexes assembled in the presence of SR
proteins that also contain various competitor RNAs are shown: 30 and
300 pmol/reaction of exon 5/WT (A, lanes 4 and
5, respectively), 30 and 300 pmol/reaction of exon 2/3/4
(A, lanes 6 and 7, respectively), 15 and 150 pmol/reaction of exon 5/WT (B, lanes 4 and 5, respectively), and 15 and 150 pmol/reaction of exon 6 (B, lanes 6 and 7, respectively). The
migration of the control RNA is indicated to the left of
each panel by a C. C, a model of SR
protein-mediated exon/exon associations in the cTnT pre-mRNA. The
SR protein-mediated association of exon 2/3/4 with exon 6 (left) is shown in competition with the SR protein-mediated
associations of both exon 2/3/4 with exon 5 (lower right)
and exon 6 with exon 5 (upper right). Although SR proteins
are depicted as directly promoting these interactions, it is likely
that they also promote these associations in cooperation with others
factors such as snRNPs.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tropomyosin pre-mRNA creates
an exonic splicing enhancer that is essential for the splicing of exons
6 and 5 (24, 25). In another case, the splicing of intron 3 of the
tumor necrosis factor-
gene is dependent upon the presence of an
additional upstream intron (26). Together, these results underscore the importance of studying an alternative splicing event in the context of
the whole pre-mRNA.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Claire Lo for technical assistance. We thank members of the Roth lab and Roy Parker for comments on the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant GM48435 (to M. B. R) and National Institutes of Health Grant HL45565 (to T. A. C).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported by National Research Service Award T32 GMO7270 from the NIGMS, National Institutes of Health. Current address: Dept. of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
To whom correspondence should be addressed. Tel.:
206-667-5602; Fax: 206-667-6877; E-mail: mroth@fred.fhcrc.org.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: snRNP, small nuclear ribonucleoprotein; cTnT, cardiac troponin T; PAGE, polyacrylamide gel electrophoresis; WT, wild type; PCR, polymerase chain reaction.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Berget, S. M.
(1995)
J. Biol. Chem.
270,
2411-2414 |
| 2. | Black, D. L. (1995) RNA (N. Y.) 1, 763-771[Medline] [Order article via Infotrieve] |
| 3. | Moore, J. M., Query, C. C., and Sharp, P. A. (1993) in The RNA World (Gestleland, R. F. , and Atkins, J. F., eds) , pp. 303-358, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 4. |
Manley, J. L.,
and Tacke, R.
(1996)
Genes Dev.
10,
1569-1579 |
| 5. | Valcarcel, J., and Green, M. R. (1996) Trends Biochem. Sci. 21, 296-301[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Zahler, A. M.,
Lane, W. S.,
Stolk, J. A.,
and Roth, M. B.
(1992)
Genes Dev.
6,
837-847 |
| 7. |
Staknis, D.,
and Reed, R.
(1994)
Mol. Cell. Biol.
14,
7670-7682 |
| 8. |
Stark, J. M.,
Bazett-Jones, D. P.,
Herfort, M.,
and Roth, M. B.
(1998)
Proc. Natl. Acad. Sci. U. S. A
95,
2163-2168 |
| 9. | Wang, Z., Hoffmann, H. M., and Grabowski, P. J. (1995) RNA (N. Y.) 1, 21-35[Abstract] |
| 10. |
Zuo, P.,
and Maniatis, T.
(1996)
Genes Dev.
10,
1356-1368 |
| 11. | Abovich, N., and Rosbash, M. (1997) Cell 89, 403-412[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Cooper, T. A.,
and Ordahl, C. P.
(1985)
J. Biol. Chem.
260,
11140-11148 |
| 13. | Ramchatesingh, J., Zahler, A. M., Neugebauer, K. M., Roth, M. B., and Cooper, T. A. (1995) Mol. Cell. Biol. 15, 4898-4907[Abstract] |
| 14. |
Grodberg, J.,
and Dunn, J. J.
(1988)
J. Bacteriol.
170,
1245-1253 |
| 15. |
Zahler, A. M.,
Neugebauer, K. M.,
Stolk, J. A.,
and Roth, M. B.
(1993)
Mol. Cell. Biol.
13,
4023-4028 |
| 16. |
Xu, R.,
Teng, J.,
and Cooper, T. A.
(1993)
Mol. Cell. Biol.
13,
3660-3674 |
| 17. |
Cooper, T. A.
(1998)
Mol. Cell. Biol.
18,
4519-4525 |
| 18. | Nagel, R. J., Lancaster, A. M., and Zahler, A. M. (1998) RNA (N. Y.) 4, 11-23[Abstract] |
| 19. | Nasim, F., Spears, P., Hoffmann, H. M., Kuo, H. C., and Grabowski, P. J. (1990) Genes Dev 7, 1172-1184 |
| 20. |
Cooper, T. A.,
Cardone, M. H.,
and Ordahl, C. P.
(1988)
Nucleic Acids Res.
16,
8443-8465 |
| 21. | Bauren, G., and Weislander, L. (1994) Cell 76, 183-192[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Beyer, A. L.,
and Osheim, Y. N.
(1988)
Genes Dev.
2,
754-765 |
| 23. | Ryan, K. R., and Cooper, T. A. (1996) Mol. Cell. Biol. 16, 4014-4023[Abstract] |
| 24. |
Helfman, D. M.,
Ricci, W. M.,
and Finn, L. A.
(1988)
Genes Dev.
2,
1627-1638 |
| 25. |
Tsukahara, T.,
Casciato, C.,
and Helfman, D. M.
(1994)
Nucleic Acids Res.
22,
2318-2325 |
| 26. |
Neel, H.,
Weil, D.,
Giasante, C.,
and Dautry, F.
(1993)
Genes Dev.
7,
2194-2205 |
This article has been cited by other articles:
![]() |
D. M. Standiford, W. T. Sun, M. B. Davis, and C. P. Emerson , Jr. Positive and Negative Intronic Regulatory Elements Control Muscle-Specific Alternative Exon Splicing of Drosophila Myosin Heavy Chain Transcripts Genetics, January 1, 2001; 157(1): 259 - 271. [Abstract] [Full Text] |
||||
![]() |
N. A. Patel, C. E. Chalfant, J. E. Watson, J. R. Wyatt, N. M. Dean, D. C. Eichler, and D. R. Cooper Insulin Regulates Alternative Splicing of Protein Kinase C beta II through a Phosphatidylinositol 3-Kinase-dependent Pathway Involving the Nuclear Serine/Arginine-rich Splicing Factor, SRp40, in Skeletal Muscle Cells J. Biol. Chem., June 15, 2001; 276(25): 22648 - 22654. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |